Basic Information
RNALocate ID: | RLID:01001725 |
RNA Symbol: | hsa-miR-23b-3p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-23b |
RNA ID: | miRBase:MIMAT0000418 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001726 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001727 | Mitochondrion | Myotube | 27396686 |
RLID:01001728 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001729 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001730 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001731 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001732 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11001669 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
RLID:11001670 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
RLID:11001671 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11001672 | Exosome | Renal cancer cells | 21670082 |
RLID:11001673 | Exosome | Ovarian follicular fluid | 22116803 |
RLID:11001674 | Exosome | Breast milk | 22211110 |
RLID:11001675 | Exosome | Brain tissue | 23382797 |
RLID:11001676 | Exosome | Plasma | 23663360 |
RLID:11001677 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11001678 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001679 | Microvesicle | Plasma | 23077538 |
RLID:11001680 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000071 | Exosome | Endothelial cells|Epithelial cells|Seminal fluid|Tongue tissue | |
RLID-D:11000346 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-23b-3p | Diffuse large b cell lymphoma | MNDR-E-MI-32119 |
MNDR | hsa-miR-23b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-32120 |
MNDR | hsa-miR-23b-3p | Oral squamous cell carcinoma | MNDR-E-MI-32121 |
MNDR | hsa-miR-23b-3p | Medulloblastoma | MNDR-E-MI-32122 |
MNDR | hsa-miR-23b-3p | B cell lymphoma of malt type | MNDR-E-MI-32123 |
MNDR | hsa-miR-23b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-32124 |
MNDR | hsa-miR-23b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-32125 |
MNDR | hsa-miR-23b-3p | Lymphoma | MNDR-E-MI-32126 |
MNDR | hsa-miR-23b-3p | Non-hodgkin lymphoma | MNDR-E-MI-32127 |
MNDR | hsa-miR-23b-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-32128 |
MNDR | hsa-miR-23b-3p | Dermatomyositis | MNDR-E-MI-32129 |
MNDR | hsa-miR-23b-3p | Prostate cancer | MNDR-E-MI-32130 |
MNDR | hsa-miR-23b-3p | Gastric cancer | MNDR-E-MI-32131 |
MNDR | hsa-miR-23b-3p | Gastric lymphoma | MNDR-E-MI-32132 |
MNDR | hsa-miR-23b-3p | Alzheimer disease | MNDR-E-MI-32133 |
MNDR | hsa-miR-23b-3p | Intracranial aneurysm | MNDR-E-MI-32134 |
MNDR | hsa-miR-23b-3p | Bladder cancer | MNDR-E-MI-32135 |
MNDR | hsa-miR-23b-3p | Esophageal carcinoma | MNDR-E-MI-32136 |
MNDR | hsa-miR-23b-3p | Dysautonomia familial | MNDR-E-MI-32137 |
MNDR | hsa-miR-23b-3p | Myotonic dystrophy | MNDR-E-MI-32138 |
MNDR | hsa-miR-23b-3p | Seizures | MNDR-E-MI-32139 |
MNDR | hsa-miR-23b-3p | Huntington disease | MNDR-E-MI-32140 |
MNDR | hsa-miR-23b-3p | Cardiovascular disease | MNDR-E-MI-32141 |
MNDR | hsa-miR-23b-3p | Carotid stenosis | MNDR-E-MI-32142 |
MNDR | hsa-miR-23b-3p | Brain cancer | MNDR-E-MI-32143 |
MNDR | hsa-miR-23b-3p | Uterine fibroid | MNDR-E-MI-32144 |
MNDR | hsa-miR-23b-3p | Lung cancer | MNDR-E-MI-32145 |
MNDR | hsa-miR-23b-3p | Down syndrome | MNDR-E-MI-32146 |
MNDR | hsa-miR-23b-3p | Parkinson disease | MNDR-E-MI-32147 |
MNDR | hsa-miR-23b-3p | Breast cancer | MNDR-E-MI-32148 |
MNDR | hsa-miR-23b-3p | Thyroid cancer | MNDR-E-MI-32149 |
MNDR | hsa-miR-23b-3p | Pituitary neoplasms | MNDR-E-MI-32150 |
MNDR | hsa-miR-23b-3p | Pancreatic cancer | MNDR-E-MI-32151 |
MNDR | hsa-miR-23b-3p | Melanoma | MNDR-E-MI-32152 |
MNDR | hsa-miR-23b-3p | Nephroblastoma | MNDR-E-MI-32153 |
MNDR | hsa-miR-23b-3p | Colon cancer | MNDR-E-MI-32154 |
MNDR | hsa-miR-23b-3p | Ischemic attack transient | MNDR-E-MI-32155 |
MNDR | hsa-miR-23b-3p | Colon adenocarcinoma | MNDR-E-MI-32156 |
MNDR | hsa-miR-23b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-32157 |
MNDR | hsa-miR-23b-3p | Familial ovarian cancer | MNDR-E-MI-32158 |
MNDR | hsa-miR-23b-3p | Prostate adenocarcinoma | MNDR-E-MI-32159 |
MNDR | hsa-miR-23b-3p | Renal cancer | MNDR-E-MI-32160 |
MNDR | hsa-miR-23b-3p | Carcinoma ductal breast | MNDR-E-MI-32161 |
MNDR | hsa-miR-23b-3p | Glioblastoma | MNDR-E-MI-32162 |
MNDR | hsa-miR-23b-3p | Glioma | MNDR-E-MI-32163 |
MNDR | hsa-miR-23b-3p | Chordoma | MNDR-E-MI-32164 |
MNDR | hsa-miR-23b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-32165 |
MNDR | hsa-miR-23b-3p | Temporal lobe epilepsy | MNDR-E-MI-32166 |
MNDR | hsa-miR-23b-3p | Osteosarcoma | MNDR-E-MI-32167 |
MNDR | hsa-miR-23b-3p | Liposarcoma | MNDR-E-MI-32168 |
MNDR | hsa-miR-23b-3p | Inclusion body myositis | MNDR-E-MI-32169 |
MNDR | hsa-miR-23b-3p | Meningioma | MNDR-E-MI-32170 |
MNDR | hsa-miR-23b-3p | Liver cancer | MNDR-E-MI-32171 |
MNDR | hsa-miR-23b-3p | Uterine cancer | MNDR-E-MI-32172 |
MNDR | hsa-miR-23b-3p | Cervical adenocarcinoma | MNDR-E-MI-32173 |
MNDR | hsa-miR-23b-3p | Gastric adenocarcinoma | MNDR-E-MI-32174 |
MNDR | hsa-miR-23b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-32175 |
MNDR | hsa-miR-23b-3p | Pituitary adenoma | MNDR-E-MI-32176 |
MNDR | hsa-miR-23b-3p | Lung squamous cell carcinoma | MNDR-E-MI-32177 |
MNDR | hsa-miR-23b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-32178 |
MNDR | hsa-miR-23b-3p | Lung adenocarcinoma | MNDR-E-MI-32179 |
MNDR | hsa-miR-23b-3p | Thyroid carcinoma | MNDR-E-MI-32180 |
MNDR | hsa-miR-23b-3p | Ovarian carcinoma | MNDR-E-MI-32181 |
MNDR | hsa-miR-23b-3p | Bladder urothelial carcinoma | MNDR-E-MI-32182 |
MNDR | hsa-miR-23b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-32183 |
MNDR | hsa-miR-23b-3p | Cervical cancer | MNDR-E-MI-32184 |
MNDR | hsa-miR-23b-3p | Carcinoma renal cell | MNDR-E-MI-32185 |
MNDR | hsa-miR-23b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-32186 |
MNDR | hsa-miR-23b-3p | Renal clear cell carcinoma | MNDR-E-MI-32187 |
MNDR | hsa-miR-23b-3p | Cholangiocarcinoma | MNDR-E-MI-32188 |
MNDR | hsa-miR-23b-3p | Esophageal cancer | MNDR-E-MI-32189 |
MNDR | hsa-miR-23b-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-32190 |
MNDR | hsa-miR-23b-3p | T acute lymphoblastic leukemia | MNDR-E-MI-32191 |
MNDR | hsa-miR-23b-3p | Acute t cell leukemia | MNDR-E-MI-32192 |
MNDR | hsa-miR-23b-3p | Fibromyalgia | MNDR-E-MI-32193 |
MNDR | hsa-miR-23b-3p | Adenoma | MNDR-E-MI-32194 |
MNDR | hsa-miR-23b-3p | Breast invasive carcinoma | MNDR-E-MI-32195 |
MNDR | hsa-miR-23b-3p | Hepatocellular carcinoma | MNDR-E-MI-32196 |
MNDR | hsa-miR-23b-3p | Familiar ovarian carcinoma | MNDR-E-MI-32197 |
MNDR | hsa-miR-23b-3p | B-cell lymphoma | MNDR-E-MI-32198 |
MNDR | hsa-miR-23b-3p | Rheumatoid arthritis | MNDR-E-MI-32199 |
MNDR | hsa-miR-23b-3p | Malignant pleural mesothelioma | MNDR-E-MI-32200 |
MNDR | hsa-miR-23b-3p | Neuroblastoma | MNDR-E-MI-32201 |
MNDR | hsa-miR-23b-3p | Hodgkin lymphoma | MNDR-E-MI-32202 |
MNDR | hsa-miR-23b-3p | Ulcerative colitis | MNDR-E-MI-32203 |
MNDR | hsa-miR-23b-3p | Neuromyelitis optica | MNDR-E-MI-32204 |
MNDR | hsa-miR-23b-3p | Acute myeloid leukemia | MNDR-E-MI-32205 |
MNDR | hsa-miR-23b-3p | Colorectal cancer | MNDR-E-MI-32206 |
MNDR | hsa-miR-23b-3p | Multiple myeloma | MNDR-E-MI-32207 |
MNDR | hsa-miR-23b-3p | Acute lymphocytic leukemia | MNDR-E-MI-32208 |
MNDR | hsa-miR-23b-3p | Uterine cervical neoplasms | MNDR-E-MI-32209 |
MNDR | hsa-miR-23b-3p | Diabetic nephropathies | MNDR-E-MI-32210 |
MNDR | hsa-miR-23b-3p | Ependymoma | MNDR-E-MI-32211 |
MNDR | hsa-miR-23b-3p | Cardiomegaly | MNDR-E-MI-32212 |
MNDR | hsa-miR-23b-3p | Nasopharyngeal cancer | MNDR-E-MI-32213 |
MNDR | hsa-miR-23b-3p | Prostatic neoplasms | MNDR-E-MI-32214 |
MNDR | hsa-miR-23b-3p | Sleep deprivation | MNDR-E-MI-32215 |
MNDR | hsa-miR-23b-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-32216 |
MNDR | hsa-miR-23b-3p | Brain injury chronic | MNDR-E-MI-32217 |
MNDR | hsa-miR-23b-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-32218 |
MNDR | hsa-miR-23b-3p | Stroke lacunar | MNDR-E-MI-32219 |
MNDR | hsa-miR-23b-3p | Low grade dysplastic nodule | MNDR-E-MI-32220 |
MNDR | hsa-miR-23b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-32221 |
MNDR | hsa-miR-23b-3p | Tubulovillous adenoma | MNDR-E-MI-32222 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ACVR2B | Homo sapiens | RR00039546 |
TOP